Virometix AG is a privately held biotechnology company developing a new generation of fully synthetic vaccines to elicit targeted and protective immune responses against infectious diseases and cancer. The company’s proprietary Synthetic Virus-Like Particle (SVLP) platform combines rational molecular design and chemical synthesis to rapidly generate optimized vaccine candidates with superior safety, efficacy, manufacturability, and stability profiles.
Leadership & Board
Current Number of Employees17
Current LinkedIn Followers1,372
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$15M
Total Amount Raised$15M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$15M
Latest Funding Amount$15M
Latest Funding RoundInvestment
Latest Funding RoundInvestment
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
Virometix AG had 17 employees as of October 5, 2026. The number of employees increased by 0 (0.00%) week-over-week.
17Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
Virometix AG had 1,372 followers as of October 5, 2026. The number of followers increased by 0 (0.00%) week-over-week.
1,372Latest Followers Count
0(0.00%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.
Funding Round
Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Nov 13, 2025
Investment
$15.00M
―
Similar Companies
A snapshot of private companies similar to Virometix AG, helping you discover and navigate related company profiles.